Výsledky vyhledávání - "Y. A. Sigidin"

Akademický článek

Infliximab in the therapy of rheumatoid arthritis

Autor: G. V. Lukina, Y. A. Sigidin, E. S. Posdnyakova, E. L. Luchihina, D. E. Karateev, E. L. Nasonov

Publikováno v: Научно-практическая ревматология, Vol 45, Iss 4, Pp 60-65 (2016)

Objective. To assess efficacy and tolerability of infliximab in pts with rheumatoid arthritis (RA) in real clinical practice.Materials and methods. 75 RA pts with high disease activity according to DAS 28 in 80% who received previous antirheumatic dr

Externí odkaz: https://doaj.org/article/6e812fb736ee4b13a325c02785a03a83

Zobrazit plný text záznamu

Akademický článek

Tyrosine kinase inhibitor Tofacitinib. Safety issues

Autor: G. V. Lukina, Y. A. Sigidin

Publikováno v: Медицинский совет, Vol 0, Iss 10, Pp 77-81 (2015)

Tofacitinib (TOFA) was the first synthetic small molecule drug which was comparable with genetically engineered biological agents (GIBA) in terms of its therapeutic effect in rheumatoid arthritis (RA). Results of treatment of over 4 thousand RA patie

Externí odkaz: https://doaj.org/article/e61d57a9424748c1ade37b2f10c3754a

Zobrazit plný text záznamu

Akademický článek

Efficacy and tolerability of abatacept treatment: results of 12 months observation

Autor: M A Borisova, G V Lukina, Y A Sigidin, E S Aronova, E L Luchihina, D E Karateev, S V Glukhova, E L Nasonov

Publikováno v: Терапевтический архив, Vol 90, Iss 5, Pp 44-49 (2018)

Objectives: This article reports 1-year clinical outcomes of patients with rheumatoid arthritis (RA) receiving abatacept (ABA) therapy. Materials and methods: Patients (n=91) with high RA activity (DAS28 = 5.1 ± 1.0) and an inadequate response on sy

Externí odkaz: https://doaj.org/article/ae4a2c7819154f0fb9ecfccd58c800b9

Zobrazit plný text záznamu